This article was originally published in The Tan Sheet
P&G expects the dilutive impact of its Gillette acquisition to reduce EPS by $.25 - $.35 in the first year after closing and $.05 -$.10 in the second year, with positive EPS growth of $.01 - $.05 in the third year, the firm says in a June 20 SEC filing. P&G's near-term strategy "must focus on the successful integration of the Gillette business and delivery of growth and cost synergies," the filing states; the firms are rumored to be mulling the divestment of certain brands to appease regulators, including products in the oral care division. P&G and Gillette recently postponed shareholder votes on the merger to July 12 and 13, respectively (1"The Tan Sheet" May 30, 2005, p. 7)...
You may also be interested in...
Preparations for Procter & Gamble's integration of Gillette are proceeding as scheduled, according to a May 24 filing with the SEC
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.
A randomized trial demonstrated the superiority of Medtronic’s DTM spinal cord stimulation waveform over conventional spinal cord stimulation for treating back pain.